Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth
SHANGHAI,Sept. 19,2022 -- Everest Medicines (HKEX 1952.HK,"Everest",or the "Company"),a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets,announced that it has appointed Rogers Yongqing Luo as Chief Executive Officer of the Company,effective immediately. Mr. Luo will also serve as an Executive Director on Everest's Board of Directors.
Mr. Luo brings to Everest more than 25 years of experience in the healthcare industry with an extensive leadership track record across clinical development,regulatory affairs and commercialization. Previously,Mr. Luo served as President and General Manager,Greater China at Brii Biosciences and CEO of TSB Therapeutics where he spearheaded the rapid registration approval,GMP certification and successful commercialization of the amubarvimab/romlusevimab combination,the first COVID-19 neutralizing antibody treatment in China. Prior to that,he was Global Vice President and China General Manager at Gilead Sciences where he led the clinical development,regulatory approval and successful commercial launch of eight innovative therapeutics,and efforts that rapidly expanded patient access across China. Mr. Luo previously oversaw the successful launch of several high-profile medicines. He managed sales,marketing,government affairs and market access functions for various leading multinational pharmaceutical companies including Roche and Novartis,and worked two years at Novartis headquarter in Switzerland.
"As Everest Medicines continues to evolve our business strategy and expand our novel product pipeline at a rapid pace,we are thrilled to have Rogers join the Company to lead Everest through its next phase of growth in becoming a fully-integrated biopharma company in China," said Mr. Wei Fu,Chairman of Everest Medicines and Chief Executive Officer of CBC Group. "With his robust background as a top executive at both biotech startup and large multinational pharma companies,Rogers brings to Everest a unique set of expertise including comprehensive scientific insight,proven outstanding leadership and excellent commercialization capabilities in patient access,and a demonstrated history of successfully advancing early- and late-stage innovative pipeline to commercial launch in Greater China. In particular,Rogers' leadership will strengthen Everest's new product development and commercial capabilities as we progress toward potential approvals of our late-stage anchor product candidates,including Nefecon,Xerava,etrasimod and mRNA vaccines. We look forward to leveraging Rogers' leadership and industry expertise to generate long-term growth and success across the business."
"I'm very excited to join Everest and I look forward to working with this talented,world-class team of scientists and industry professionals to further the Company's industry leadership. We will continue to advance our late-stage pipeline towards commercialization and with our strong balance sheet,we aim to execute synergistic business development deals to accelerate our path to become an integrated biopharma," said Rogers Yongqing Luo,Chief Executive Officer of Everest Medicines. "We will continue to invest into our discovery platform to build an innovative therapeutic pipeline for the benefit of patients with unmet needs in Greater China and other Asia Pacific markets,and to create sustained,long-term value for our shareholders."
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development,regulatory affairs,CMC,business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules,many of which are in late-stage clinical development. The Company's therapeutic areas of interest include oncology,autoimmune disorders,cardio-renal diseases and infectious diseases. For more information,please visit its website atwww.everestmedicines.com.
Forward-Looking Statements:
This news release may make statements that constitute forward-looking statements,including descriptions regarding the intent,belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company,which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties,or other factors,some of which are beyond the control of the Company and are unforeseeable. Therefore,the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions,such as future changes and developments in our business,competitive environment,political,economic,legal and social conditions. The Company or any of its affiliates,directors,officers,advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information,future events or circumstances after the date of this news release,except as required by law.
